Document ID: chunk:federal_register_of_legislation:F2018L01746:clause:2_19
Version: federal_register_of_legislation:F2018L01746
Segment Type: clause
Provision Reference: sch 2 cl 19
Character Range: 14602–16301

19                                       updated                                         date that the entry was last updated

In this Part:
  low impact, in relation to a shortage of a reportable medicine that is not of critical impact, means a shortage that is assessed as low patient impact in accordance with the assessment framework set out in the Management and Communication of Medicine Shortages and Discontinuations in Australia – Guidance for Sponsors and Other Stakeholder Bodies published in November 2018.
  medium impact, in relation to a shortage of a reportable medicine that is not of critical impact, means a shortage that is assessed as medium patient impact in accordance with the assessment framework set out in the Management and Communication of Medicine Shortages and Discontinuations in Australia – Guidance for Sponsors and Other Stakeholder Bodies published in November 2018.
Note:  The Management and Communication of Medicine Shortages and Discontinuations in Australia – Guidance for Sponsors and Other Stakeholder Bodies can be found (and viewed for free) on the internet at: http://www.tga.gov.au.

Part 2— Information relating to a decision to permanently discontinue the supply of a reportable medicine that is made on or after 1 January 2019

For each item in column 1 of the following table, the kind of therapeutic goods information specified in column 2 has the description given in column 3.

Kinds of  therapeutic goods information
Column 1                                 Column 2                                    Column 3

Item                                     Information                                 Description
Information about the medicines: